Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.

Gennaro PaganoFlavia NiccoliniHeather WilsonTayyabah YousafNaheed L KhanDavide MartinoChristophe PlissonRoger N GunnEugenii A RabinerPaola PicciniThomas FoltynieMarios Politis

Published in: Movement disorders : official journal of the Movement Disorder Society (2019)

Our findings demonstrate loss of phosphodiesterase 10A levels very early in the course of PD and is associated with the gradual and progressive increase of motor symptoms. Phosphodiesterase 10A imaging shows similar potential with dopamine transporter imaging to follow disease progression. © 2019 International Parkinson and Movement Disorder Society.

Keyphrases

high resolution
uric acid
multiple sclerosis
risk assessment
risk factors
fluorescence imaging
photodynamic therapy